Replies to post #207331 on Innovation Pharmaceuticals Inc (IPIX)

[DoubleJ23]

You rock, CABEL. Real, clear answers from the person who matters!

Thank you!

[TheDane]

Thanks. Good replies from Leo.

[tryz]

Thanks cabel!....great feedback from Leo and have no concerns what so ever ....this stock and company with prosper in the coming weeks.....this who sold or those manipulaters will pay dearly and pos ter Claytrader and his sheep are complete dikheads as usual .....tryz

[Bruinfan4ever]

That's from up to 3 out of 4 down to about 1 in 3. that's huge. If you use a million scale, that is up to 750.000 getting severe OM down to 360,000. That's huge.

[DaubersUP]

Awesome!!!! Thanks

[WILD_4_IPIX]

Thanks Cabel....

GO IPIX !

[zandant]

Hmmm. Maybe he should have written the pr that way. I am hoping that the pps is being driven down in part because traders focused on the figures - they saw 60% placebo and 39% Brilacidin - without really looking at it in its true context and assumed the placebo rate prevailed.

[Rdunn88]

The reason why the stock is dropping is the low patient participation with only 30 percent efficiency. Phase 3 will need 200 plus patients with minimum funding on-hand. Without partnership, OM is dead unless the stock can rally on P results. Throw OM in the closet with UP/ABSSSI.

[JUST 10-11-12]

Great

[JUST 10-11-12]

Great

[govorchin]

Thank you. Easy to understand

[someday7]

I call Bull Shat. Read the article fully already have duration results. All u need to know is no p-data. Trial manipulated to show the results it did more than likely in a real trial it would show little to no effect.

[JTORENCE]

cabel your post with Leo should be a sticky.imo

[Phoenix300]

Thanks for sharing

[bunky]

When can we expect secondary endpoints???


thank you

charlieB

[sox040713]

Thanks for confiming the plan to apply BTD. It’s a no-brainer given its 63.2% in severe OM prevention.

I believe Phase 3’s protocol will be similar to Phase 2. Perhaps the FDA will allow one more B-OM arm with higher concentration since systemic absorption is very low.

Looking forward to secondary endpoints. Severe OM duration is also important since that’s the primary endpoint for most competitors.